Market Overview

UPDATE: Ascendiant Capital Markets Downgrades PhotoMedex Following Completion Of LCA Vision Acquisition

Related PHMD
20 Biggest Mid-Day Gainers For Wednesday
Mid-Day Market Update: Twilio Tumbles On Weak Guidance; Pieris Pharma Shares Climb

In a report published Thursday, Ascendiant Capital Markets analyst Keay Nakae downgraded the rating on PhotoMedex (NASDAQ: PHMD) from Buy to Hold, and removed the $18.00 price target.

In the report, Ascendiant Capital Markets noted, “The acquisition of LCA Vision has now been completed. The objective of this acquisition is to leverage LCA's 62 existing stand-alone LasikPlus centers, to perform Xtrac procedures. The Company will fund this $106.5 MM transaction through a new $85 MM senior secured credit facility ($75 MM to fund the acquisition and a $10 MM line of credit) and about $3 MM in net cash.”

PhotoMedex closed on Wednesday at $12.27.

Latest Ratings for PHMD

Nov 2014Canaccord GenuityMaintainsHold
Aug 2014Canaccord GenuityDowngradesBuyHold
May 2014AscendiantDowngradesBuyHold

View More Analyst Ratings for PHMD
View the Latest Analyst Ratings

Posted-In: Ascendiant Capital Markets Keay NakaeAnalyst Color Downgrades Analyst Ratings


Related Articles (PHMD)

View Comments and Join the Discussion!